Regeneron Gets $407M After Antitrust Win Over Amgen

Regeneron won a $406.8 million judgment in its antitrust suit against Amgen, following a jury verdict last month saying Amgen illegally undercut the price of Regeneron's anticholesterol drug Praluent through a...

Already a subscriber? Click here to view full article